[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-cancers":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,55,89,112,137,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100552955","phase-1-212pbvmt-alpha-net-in-metastatic-or-inoperable-somatostatin-receptor-positive-gastrointestinal-neuroendocrine-tumors-pheochromocytomaparagangliomas-small-cell-lung-renal-cell-and-head-and-neck-cancers-100552955",false,"NCT06479811","[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","* INCLUSION CRITERIA:\n* Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma\u002Fparaganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \\& Neck cancers (nasopharyngeal carcinoma \\[NPC\\], olfactory neuroblastoma \\[ONB\\], sinonasal neuroendocrine carcinoma \\[SNEC\\]) that are metastatic or inoperable per Standard of Care. Note: for KC, all histopathologies of kidney cancers are eligible as long as it is a primary renal neoplasm.\n* Required prior therapies:\n* GI NET, PPGL, H\\&N: no specific prior therapy is needed.\n* SCLC: At least one prior line of standard of care systemic treatment such as chemotherapy and\u002For immunotherapy.\n* KC: Renal cell carcinoma (RCC) participants should have received at least one line of prior therapy in the metastatic setting and should have received at least one Programmed cell death protein 1 (PD1) \u002F Programmed death-ligand 1 (PDL1)-targeted immune checkpoint inhibitor as well as one agent targeting the VEGF pathway. Participants with fumarate hydratase (FH) deficient RCC should have received at least one prior line of systemic therapy (such as bevacizumab plus erlotinib). No prior therapy is needed for participants with other histologic subtypes.\n* Have NOT received prior systemic radioligand therapy for definitive therapeutic purposes. Prior external beam radiation therapy is allowed.\n* History of disease progression by imaging (e.g., RECIST 1.1) or clinically (defined as increase in severity or frequency of symptoms related to disease) within the past 36 months prior to the first dose of \\[203Pb\\]VMT-Alpha-NET.\n* Evidence of somatostatin receptors (SSTR) expression on at least 50% of the radiographically identifiable (i.e., visible on an anatomic scan such as CT or magnetic resonance imaging \\[MRI\\]) tumor, as indicated by a positive (uptake qualitatively identifiable as above the local background) on SSTR PET scan.\n* Age \\>= 18 years.\n* ECOG performance status \\\u003C=1.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Leukocytes: 3,000\u002Fmicroliter\n  * Absolute Neutrophil Count: 1,500\u002Fmicroliter\n  * Platelets 100,000\u002Fmicroliter\n  * Hemoglobin \\>= 9.0 g\u002FdL\n  * Total bilirubin: within normal institutional limits. Note: \\\u003C= 5 X institutional upper limit of normal (ULN) if bilirubin elevation is due to a benign process such as Gilbert syndrome\n  * AST: \\\u003C= 2.5 X institutional ULN\n  * ALT: \\\u003C= 2.5 X institutional ULN\n  * Creatinine: within normal institutional limits\n\nOR\n\n* Calculated creatinine clearance (glomerular filtration rate (eGFR): \\>= 60 mL\u002Fmin\u002F1.73 m\\^2 for participants with creatinine levels above institutional normal\n\n  * Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression at screening.\n  * Participants with new or progressive brain metastases or leptomeningeal disease are eligible as long as the participant is asymptomatic and not requiring medication for symptom control from the brain lesions at screening.\n  * Participants seropositive for human immunodeficiency virus (HIV) must:\n* be on effective anti-retroviral therapy; and\n* have an undetectable viral load at screening.\n\n  * Participants seropositive for hepatitis B virus (HBV), must have HBV viral load undetectable at screening.\n  * Participants seropositive for hepatitis C virus (HCV) must:\n* received curative treatment; and\n* have an undetectable HCV viral load at screening.\n\n  * Individuals of child-bearing potential (IOCBP) and individuals who can father children must agree to use an effective method of contraception (barrier, hormonal, intrauterine device \\[IUD\\], surgical sterilization, abstinence) at study entry and up to 6 months after the last dose of the study agent(s).\n  * Nursing participants must be willing to discontinue nursing from study treatment initiation through 6 months after the last dose of the study agents.\n  * The ability of the participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Any investigational agents should be stopped at least 28 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET.\n* Systemic therapy should be stopped at least 28 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET (participants with prior systemic therapies for their malignancy only, except participants with SCLC).\n* Systemic therapy should be stopped at least 14 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET (participants with SCLC only).\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to VMT-Alpha-NET.\n* Positive Beta human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test performed in IOCBP at screening.\n* QTc \\> 450 ms on electrocardiogram (EKG) at screening. Note: Framingham correction for QTc will be used\n* History of or detection at screening of active\u002Funtreated secondary malignancy except nonmelanoma skin cancer and carcinoma in situ of the uterine cervix.\n* Uncontrolled intercurrent illness, factors, evaluated by medical history and physical exam which would potentially increase in the risk of the participant.","ALL","18 Years","120 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\nSome cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Researchers want to know if drug treatments that target SSTRs can help shrink these types of tumors.\n\nObjective:\n\nTo test a study drug (\\[212Pb\\]VMT-Alpha-NET) in people with tumors that have SSTRs.\n\nEligibility:\n\nPeople aged 18 years and older with tumors of the lung, kidneys, head and neck, digestive tract, or adrenal glands that have SSTRs. Their tumors must have spread to other organs and cannot be removed with surgery.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and a test of their heart function. A sample of tumor tissue may be collected if one is not already available.\n\n\\[212Pb\\]VMT-Alpha-NET is given through a tube attached to a needle inserted into a vein. The drug will be given on the first day of four 8-week cycles. Participants will stay in the hospital for a few nights after each dose. They will have blood tests once a week during each cycle.\n\nSome participants will also get a related study drug (\\[203Pb\\]VMT-Alpha-NET). They will receive this drug a few days before the first 2 cycles. At 4, 24, and 48 hours after each infusion, they will have whole body scans. These scans will show where the study drug went in their body.\n\nFollow-up visits will continue up to 6 years after the last treatment.",[27,28,29,30,31,32,33,34,35,36],"Sinonasal Neuroendocrine Carcinoma","Nasopharyngeal Carcinoma","Esthesioneuroblastoma","Olfactory Neuroblastoma","Somatostatin Receptor Positive","Small Cell Lung Cancers","Pheochromocytoma\u002FParagangliomas","Kidney Cancers","Head and Neck Tumors","Gastrointestinal Neuroendocrine Tumors",[38,39,40,41],"212Pb","Targeted alpha Therapy","Image-Guided Dosimetry","VMT-alpha-NET","RECRUITING","2026-06-11",{"date":45,"type":46},"2026-06-12","ACTUAL",{"date":48,"type":46},"2025-08-19",{"date":50,"type":21},"2032-01-01",{"name":52,"class":53},"National Cancer Institute (NCI)","NIH",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":75,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100616025","phase-1-open-label-phase-12-study-of-neo-811-in-subjects-with-locally-advanced-or-metastatic-non-resectable-clear-cell-renal-cell-carcinoma-100616025","NCT07300241","Open-Label Phase 1\u002F2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma","An Open-Label, First-in-Human, Phase 1\u002F2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC).\n* Subjects must have progressed on or refused standard therapies.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.\n* Estimated life expectancy, in the judgment of the Investigator, of at least 12 weeks.\n* Formalin-fixed paraffin-embedded (FFPE) tumor tissue, newly obtained or archival, is mandatory for enrollment to the study.\n* Measurable disease as defined by RECIST v1.1.\n* Adequate hematologic, hepatic, and renal function defined as:\n\n  * Hemoglobin ≥10 g\u002FdL,\n  * Absolute neutrophil count ≥1000 cells\u002FµL,\n  * Platelet count ≥100,000\u002FµL,\n  * AST and ALT ≤2.5 × ULN, or AST and ALT ≤5 × ULN for subjects with liver metastases,\n  * Total bilirubin ≤1.5 × ULN,\n  * Estimated glomerular filtration rate (eGFR) ≥60 mL\u002Fmin.\n* Subject can swallow oral medications and does not have a condition that could impair the oral bioavailability of the study drug.\n* Other inclusion criteria per protocol.\n\nExclusion Criteria:\n\n* Non-clear cell predominant RCC histologic subtypes.\n* Leptomeningeal disease or symptomatic active CNS metastases with exceptions for asymptomatic treated CNS metastases per protocol.\n* Prior or concurrent malignancies with exceptions per protocol.\n* History of hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV infection.\n* Other exclusion criteria per protocol.",{"count":63,"type":21},30,[24],"The NEO-811-101 study is an open-label, first-in-human, Phase 1\u002F2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.",[67,68,69,70,71,72,73,74,34],"Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma","RCC","Clear Cell Renal Cell Carcinoma Metastatic","ccRCC","VHL-Associated Clear Cell Renal Cell Carcinoma","VHL-Associated Renal Cell Carcinoma","Kidney Cancer Metastatic",[71,68,67,76,77],"VHL","Kidney Cancer","2026-05-29",{"date":80,"type":46},"2026-06-02",{"date":82,"type":46},"2025-12-19",{"date":84,"type":21},"2027-09",{"name":86,"class":87},"Neomorph, Inc","INDUSTRY",10,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":54},"100637444","early-phase-1-clinical-application-of-caix-targeted-pet-imaging-in-tumors-100637444","NCT07590310","Clinical Application of CAIX-Targeted PET Imaging in Tumors","Inclusion Criteria:\n\n-Hematological, hepatic, and renal functions meeting the following criteria: Complete Blood Count: WBC ≥4.0×10⁹\u002FL or Neutrophils ≥1.5×10⁹\u002FL, PLT ≥100×10⁹\u002FL, Hb ≥90 g\u002FL; Coagulation: PT or APTT ≤1.5 × ULN (Upper Limit of Normal); Hepatic Function: T-Bil ≤1.5 × ULN; ALT\u002FAST ≤2.5 × ULN (or ≤5 × ULN for subjects with liver metastases); ALP ≤2.5 × ULN (or ≤4.5 × ULN for subjects with bone or liver metastases); Renal Function: BUN ≤1.5 × ULN, SCr ≤1.5 × ULN.\n\nNormal cardiac function;\n\n* Expected survival ≥12 weeks;\n* Good compliance with follow-up;\n* At least one measurable target lesion according to RECIST 1.1 criteria;\n* Women of childbearing potential (aged 18-49) must have a negative pregnancy test within 7 days prior to the examination. Male and female patients of childbearing potential must agree to use effective contraception to prevent pregnancy during the study and for 3 months after the examination;\n* Patients for whom the clinician recommends a PET\u002FCT examination for tumor diagnosis and staging;\n* Patients are fully capable of understanding the study, voluntarily agree to participate, and provide written informed consent.\n\nExclusion Criteria:\n\n* Severe abnormalities in hepatic, renal, or hematological function;\n* Patients planning for pregnancy;\n* Pregnant or lactating women;\n* Inability to lie flat for 30 minutes;\n* Refusal to participate in this clinical study;\n* Presence of claustrophobia or other psychiatric disorders;\n* Any other condition deemed unsuitable for participation by the investigator.","75 Years",{"count":97,"type":21},3,[99],"EARLY_PHASE1","According to the 2020 global cancer statistics, renal carcinoma ranks as the fourteenth most common malignant tumor worldwide. In 2020, there were 431,288 new cases and 179,368 deaths from renal cancer, and both the incidence and mortality rates are projected to continue rising by 2025. Early non-invasive diagnosis of clear cell renal cell carcinoma (ccRCC) is crucial for improving prognosis. Nuclear medicine molecular imaging offers the advantages of real-time, dynamic, and non-invasive detection of lesions throughout the body. However, there is currently a lack of highly efficient and targeted molecular probes for early and accurate diagnosis of this tumor in clinical practice.\n\nThe high expression of CAIX plays a central role in the pathogenesis of renal cancer by altering cellular metabolism, inducing angiogenesis, promoting epithelial-mesenchymal transition (EMT), invasion, and metastatic spread. CAIX is highly expressed in 95% of ccRCC cases. In fact, CAIX expression levels have been reported as an independent predictor of survival in advanced ccRCC. Moreover, CAIX expression in normal tissues is limited, primarily restricted to the stomach, the basolateral aspects of proliferating small intestinal crypt epithelial cells, and the gallbladder. Therefore, the differential expression of CAIX between ccRCC tumors and normal tissues highlights its potential as a robust target for nuclear medicine molecular probe research and development in ccRCC.\n\nThis study utilized high-throughput screening to identify small molecules with high affinity for CAIX. These molecules were subsequently cyclized and modified to enhance their in vivo stability. A bifunctional chelator, H3RESCA, was introduced at the C-terminus to construct the small-molecule compound RESCA-CAIX-LT. PET probes were prepared by radiolabeling with 68Ga or 18F, and their diagnostic efficacy for renal cancer was investigated. Small-animal PET imaging initially demonstrated that the probe exhibits high affinity and excellent imaging performance. The modifications also altered the in vivo metabolic profile of the original design, reducing non-specific uptake in organs such as the stomach, small intestine, and gallbladder. Furthermore, toxicological experiments confirmed the probe's high safety profile and in vivo stability.",[34],"2026-05-08",{"date":104,"type":46},"2026-05-15",{"date":106,"type":46},"2025-03-01",{"date":108,"type":21},"2026-12-31",{"name":110,"class":111},"Peking University Cancer Hospital & Institute","OTHER",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":54},"100596845","phase-2-comprehensive-multimodal-prehabilitation-alone-or-with-neoadjuvant-therapy-before-major-cancer-surgery-100596845","NCT07050771","Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery","Comprehensive Multimodal Prehabilitation Alone or in Combination With Planned Neoadjuvant Therapy in High-risk Patients Prior to Elective Major Cancer Surgery","Inclusion Criteria:\n\nPatients are eligible for entry into the study (First Registration) only if ALL of the following criteria apply. No exceptions or waivers will be granted for patients who do not meet the eligibility criteria.\n\n* Signed informed consent form.\n* Age ≥18 years at time of signing informed consent form.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 per the treating cancer surgeon (Arm 1, Neoadjuvant therapy) or per both the treating cancer surgeon and the medical and\u002For radiation oncologists (Arm 2, no neoadjuvant therapy).\n* Pre-frail or frail (based on the Fried Frailty Phenotype\n* Probable or proven (histologically confirmed) pancreaticobiliary\u002Fperiampullary (i.e., pancreatic cancer, cholangiocarcinoma, duodenal cancer, or ampullary cancer), ovarian cancer, kidney cancer, or bladder cancer based on central pathological review at Houston Methodist Hospital.\n* Clinically non-metastatic (stage I-III) or metastatic (IV) disease.\n* Technically resectable disease (no significant vascular, neural, or bony involvement and potential to safely achieve R0 resection) and potentially medically fit for EMCS per the treating cancer surgeon (surgical oncologist\u002FHBP surgeon, gynecologic oncologist, or urologic oncologist).\n* Tentatively scheduled to undergo elective pancreatectomy (open or minimally invasive pancreaticoduodenectomy or open distal pancreatectomy) for pancreaticobiliary\u002Fperiampullary cancer, elective surgical cytoreduction for ovarian cancer, elective open radical nephrectomy for kidney cancer, or elective (open or minimally invasive) total cystectomy for bladder cancer by one of the study MPI or Co-Is \\> 28 days after trial registration.\n* Neoadjuvant therapy group only: Completed planned NAT (if any) at least 2 weeks prior to Study Registration.\n* No neoadjuvant therapy group only: Medically fit and planned to receive NAT per the treating medical and\u002For radiation oncologist.\n* Ability to comply with the CMMP intervention and study assessments as per protocol, in the MPI's judgment.\n* Willing and able to consume a lactose-free, whey protein supplement (if not allergic to milk protein\u002Fsoy and no history of galactosemia), marine protein supplement (if not allergic to marine protein\u002Fshellfish), or pea protein supplement (if not allergic to pea protein).\n* Willing to provide tissue and blood specimens as per protocol.\n* For patients receiving therapeutic anticoagulation: stable anticoagulant regimen.\n* Access to a smart phone (personally or via caretaker who resides with the patient).\n* Understands, speaks, and reads English.\n\nExclusion Criteria:\n\nPatients are NOT eligible for entry into the study (First Registration) only ANY of the following criteria apply. No exceptions or waivers will be granted for patients who do not meet the eligibility criteria.\n\n* Difficulty or inability to hear and\u002For understand loud speech and sounds.\n* Unable to eat by mouth (e.g., tube feed dependent, on total parenteral nutrition, etc.)\n* Oxygen dependent (or rest and\u002For with exertion).\n* Significant cardiovascular disease (such as New York Heart Association (NYHA) Functional Classification III or IV, unstable angina, unstable arrhythmia, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of trial treatment.\n* Dependence on mobility device for ambulation other than a cane (e.g., crutches, walker, wheelchair).\n* Active brain metastasis or leptomeningeal disease.\n* Active bone metastasis and\u002For recent bone fracture.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). NOTE: Patients with indwelling catheters (e.g., PleurX) are allowed\n* Planned receipt of investigational therapy\u002Ftreatment (other than the protocol-mandated CMMP intervention) during the trial treatment.\n* Major procedure\u002Fsurgery within 12 weeks prior to initiation of trial treatment that would prevent the patient from complying with the CMMP intervention and study assessments as per protocol, in the MPI's judgment.\n* Active physical\u002Fmental condition or personal\u002Fsocial circumstance that would prevent the patient from complying with the CMMP intervention and study assessments as per protocol, in the MPI's judgment.",{"count":120,"type":21},148,[122],"PHASE2","In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail\u002Ffrail patients with probable\u002Fproven pancreaticobiliary, ovarian, kidney, or bladder cancer prior to elective major cancer surgery (EMCS).",[125,126,34,127],"Hepatopancreaticobiliary (HPB) Malignancy","Ovarian Cancer (OvCa)","Bladder Cancer","2026-03-10",{"date":130,"type":46},"2026-03-12",{"date":132,"type":46},"2025-08-14",{"date":134,"type":21},"2027-10-01",{"name":136,"class":111},"The Methodist Hospital Research Institute",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":16,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":54},"100606103","targeted-abdominal-ct-in-conjunction-with-lung-cancer-screening-100606103","NCT07171190","Targeted Abdominal CT in Conjunction With Lung Cancer Screening","Targeted Abdominal CT in Conjunction With Lung Cancer Screening - a Pilot Study (TACTICAL1): a Randomised Controlled Pilot Study of Adding Abdominal Non-contrast CT to Lung Cancer Screening CT Thorax Amongst High Lung Cancer Risk Ever-smokers Aged 55-70.","TACTICAL1","1. For the individual level randomisation to invitation control or invitation intervention\n\n   Inclusion criteria: To be randomised at the individual level to receive an invitation letter for LCS (standard of care; invitation control) versus invitation letter for LCS with potential for an additional abdominal scan (invitation intervention):\n   * Be eligible to be invited to the first round of a West Yorkshire and Harrogate LCS or a Humber and North Yorkshire Cancer Alliance LCS (i.e. have been identified as a smoker or ex-smoker and registered as living within the relevant LCS catchment area).\n   * Be registered with a GP in England.\n   * Be aged 55-70 years 364 days old at the date of invitation.\n\n   Exclusion criteria\n\n   • None\n2. Eligibility criteria for the cluster level randomisation to scan intervention or scan control\n\n   Inclusion criteria a): To be eligible for the cluster level randomisation the participant must:\n   * Have been individually randomised to the invitation intervention arm\n   * Have booked in for a LCS assessment\n\n   Inclusion criteria b): To receive the CT Thorax plus ANCCT, the participant must:\n   * Have been randomised to the scan intervention cluster\n   * Be invited to attend for a LDCT Thorax based upon scores on either PLCOM2012 or Liverpool Lung Project (LLP) risk prediction models (PLCOM2012 risk of ≥1.51% over six years or LLPver2 five-year risk of ≥2.5%)14 during the LCS assessment.\n   * Have attended the lung scan appointment\n   * Have given electronic or written informed consent to participate\n\n   Exclusion criteria\n\n   Existing LCS exclusion criteria:\n   * Participant does not have capacity to give consent (standard criteria for assessing capacity apply).\n   * Weight or physical size exceeds restrictions for scanner (\\>200kg).\n   * Participant unable to lie flat.\n   * Poor physical fitness such that treatment with curative intent would be contra-indicated.\n   * Participants who have had a full CT Thorax that meets the image reconstruction parameters of the programme in the last 12 months are not excluded from the lung screening programme, but would have their CT Thorax appointment deferred until 12 months have elapsed since that last scan, provided they still meet all inclusion criteria and have no exclusion criteria - if the deferred appointment is within the timeframe for TACTICAL1, they remain eligible but if deferred appointment is outside the timeframe for TACTICAL1 they would not be eligible.\n\n   Additional TACTICAL1 exclusion criteria:\n\n   • Had an abdominal CT in the previous 12 months or has one booked within the next 3 months.\n   * For HNY, this is checked before the LCS assessment. Therefore, participants will be excluded before the LCS assessment.\n   * For WYH, this is only checked after the LCS assessment. Therefore, anyone having had an abdominal CT in the previous 12 months or with one booked within the next 3 months will be excluded at this point (see 8.6).\n3. Eligibility criteria for the process evaluation Health care professionals: Healthcare professionals involved in the delivery of LCS in any of the study areas who agree to take part.\n\nParticipants: People individually randomised to the invitation intervention arm who attend the LCS assessment or the scanning unit within the study period and who agree to be interviewed.",true,"55 Years","70 Years",{"count":149,"type":21},6272,[151],"NA","Early detection through screening can improve cancer survival by identifying it when it's most treatable. The NHS now offers Lung Cancer Screening (LCS) assessments to people aged 55-74 who have ever smoked. Those at higher risk of lung cancer are offered a lung scan.\n\nThis group also has a high risk of developing abdominal cancers, such as kidney cancer. A recent study explored whether it would be feasible to extend the lung scan to include the abdomen. Results showed most participants supported this addition, and the number of serious findings was similar to those detected in UK breast or bowel cancer screening programmes.\n\nHowever, the abdominal scan was only offered on the day of the lung scan, giving little time for people to consider their decision. The process also added too much time to be practical for widespread implementation.\n\nThis new study will:\n\n* Test whether mentioning the possible abdominal scan in the initial LCS invitation affects participation in LCS assessments.\n* Test new processes to assess if the abdominal scan can be added to the lung scan with minimal extra time.\n* Check if participants can be split between the lung scan only group and lung and abdominal scan group using an approach called 'cluster randomisation'. This will be important in case a bigger trial is needed.\n* See whether the additional processes are acceptable\n\nPeople aged 55-70 who are invited to the lung cancer screening will be eligible to take part in this study. Only those who are found to be at a high risk of lung cancer after their assessment, and therefore offered a lung scan, will be offered the abdominal scan, provided they have not had an abdominal scan in the previous 12 months or one booked in the next 3 months.\n\nThis study will take place in two existing lung cancer screening locations in Yorkshire.",[154,34,155,156],"Renal Cell Carcinoma (Kidney Cancer)","AAA - Abdominal Aortic Aneurysm","Renal Stones",[158,159,160,161,162,163,164],"Screening","NHS Lung Cancer Screening","Kidney cancer","Abdominal cancer","Lung cancer","Abdominal Aortic Aneurysms (AAA)","Abdominal screening","2025-12-12",{"date":82,"type":46},{"date":168,"type":46},"2025-11-11",{"date":170,"type":21},"2027-10",{"name":172,"class":111},"University of Cambridge",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":192,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":54},"100573386","prehabilitation-prior-to-surgery-for-kidney-tumors-100573386","NCT06745609","Prehabilitation Prior to Surgery for Kidney Tumors","Prehabilitation Prior to Surgery for Kidney Tumors: A Randomized Controlled Research Study (Pre-KiT)","Pre-KiT","Inclusion Criteria:\n\n* 65 years or older\n* cT1 kidney tumor, scheduled for either partial or radical nephrectomy.\n* Clinical Frailty Scale 3-6\n\nExclusion Criteria:\n\n* It is determined by an attending physician, or at a multi-disciplinary team-conference, that a 2-4 week postponement of surgery will not be beneficial for the participant.\n* Participant does not understand Danish og English","65 Years",{"count":183,"type":21},60,[151],"The goal of this clinical trial is to examine if one month of general health optimization before surgery for kidney tumors can help participants recover more quickly from surgery.\n\nThe optimization process is called prehabiliation, and will last one month. It consists of\n\n1. A comprehensive health assessment\n2. Assisted smoking cessation\n3. A home exercise program.\n\nThe investigators will compare an intervention group receiving one month of prehabilitation with a control group receiving the standard of care.\n\nSome of the main questions the investigators want to answer are\n\n* Are participants in the intervention group more satisfied with their quality of recovery after surgery?\n* Do participants in the intervention group maintain more of their physical abilites compared to the control group?",[187,188,34,189,190,191],"Renal Cancer","Renal Cell Cancer","Stage I Renal Cell Cancer","Prehabilitation","Elderly (People Aged 65 or More)",[190,193,194,195,196,160,197,198],"Quality of life","Kidney tumor","Renal cell tumor","Renal cell cancer","Quality of recovery","Elderly","2025-01-22",{"date":201,"type":46},"2025-01-24",{"date":203,"type":46},"2025-01-21",{"date":205,"type":21},"2032-03",{"name":207,"class":111},"Herlev and Gentofte Hospital"]